RSS Feed ALL

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

1 day ago

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk...

Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

2 days ago

New data from Cohort 4 of the SunRISe-1 study show more than...

Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40

4 days ago

New survey reveals Americans overlook eye health—despite its impact on confidence, independence...

Johnson & Johnson receives European Commission approval of IMAAVY®▼ (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)

5 days ago

Nipocalimab is the first FcRn blocker approved in both adult and adolescent...

Johnson & Johnson Statement on the Auτonomy Study

16 days ago

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

20 days ago

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week...

Johnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics

20 days ago

Acquisition provides highly differentiated clinical-stage treatment for prostate cancer, building on Johnson...

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

about 1 month ago

Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of...

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

about 1 month ago

CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a...

Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference

about 1 month ago

Johnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research

about 1 month ago

More than 60 abstracts spotlight leading portfolio and pipeline of innovative medicines...

Johnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking Presentation at VIVA 2025

about 1 month ago

Findings demonstrate durable benefits and low complication rates, enabling treatment for severely...